Laurent Fischer, Adverum CEO (Frazier Healthcare Partners)
April 28, 2021 04:42 PM EDTUpdated 05:04 PM
Cell/Gene Tx

Gene ther­a­py tri­al is de­railed af­ter get­ting hit by the lat­est se­ri­ous ad­verse event in the field — shares crash

John Carroll

Editor & Founder

You can rack up an­oth­er se­ri­ous safe­ty con­cern flagged by a gene ther­a­py de­vel­op­er.

To­day it’s Ad­verum, which is re­port­ing that a pa­tient who re­ceived …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times